Research
Anticoagulants Reign Supreme in VTE Prevention After Joint Replacement
The Brief
- In the randomized PEPPER trial, aspirin did not prevent venous thromboembolism (VTE) as well as anticoagulants did in patients undergoing elective hip or knee replacement.
- The trial's primary composite endpoint included death from VTE-related causes; the full endpoint definition is not given in the available source excerpt.
Why it matters
The results bear on which thromboprophylaxis drug is chosen after elective hip or knee replacement, a common procedure where VTE is a recognised risk.
Who’s affected
- orthopedic surgeons and hospital teams managing elective joint replacement
- patients undergoing elective hip or knee replacement
- #venous thromboembolism
- #joint replacement
- #anticoagulants
- #aspirin
- #clinical trial
(MedPage Today) -- Aspirin didn't prevent venous thromboembolism (VTE) as well as anticoagulants did for patients undergoing elective hip or knee replacements, the randomized PEPPER trial showed. For the primary composite endpoint of death from...